Venus-PowerX is Venus Medtech’s next-generation self-expanding dry-tissue TAVR system for the treatment of patients with aortic valve stenosis. Venus-PowerX utilizes the innovative Venus-Endura technology, which integrates multiple anti-calcification techniques, immunogenicity removal technology and 3D force-controlled dehydration technology, providing exceptional durability, biocompatibility, and excellent anti-calcification performance. In addition, this design allows room temperature storage of the valve in a dry-tissue condition.

Venus-PowerX features a unique wire-controlled function that allows for full retrieval of the valve after 100% release which enhances the safety of implantation. In addition, the PowerX Delivery System adopts a new design that optimizes its flexibility to go through the aortic arch. The three V-shaped outflow portions of the valve are designed to preserve space for coronary access post implant, whilst also retaining excellent radial force.

Venus-PowerX's self-adaptive anti-PVL technology utilizes an adaptive polymer skirt. The proprietary polymer skirt material possesses a high compression ratio, excellent resilience, self-expanding properties with adaptive sealing. It demonstrates adaptive deformation during valve crimping, without enlarging the profile of the delivery system. Upon deployment, it actively fills the gaps around the valve perimeter, achieving remarkable anti-PVL performance.

Venus-PowerX was granted approval in Argentina and Chile in 2023 successively.